Health Care's Elite Eight Stocks: Johnson & Johnson vs. Novartis

By Max Macaluso – Apr 4, 2013 at 6:30PM

NYSE: JNJ

Johnson & Johnson

Market Cap

$349B

Today's Change

(0.22%) $0.32

Current Price

$144.77

Price as of April 17, 2024, 4:00 p.m. ET

Who will prevail in this head-to-head match-up?

Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Wichita State have busted the brackets of would-be basketball prognosticators.

Here at The Motley Fool, we decided to stick with what we know -- trading our basketball picks in for stock picks. We formed our own bracket filled with the top big pharma and big biotech stocks in a winner-take-all tournament as determined by the collective intelligence of our CAPS community.

This Elite Eight matchup is a heavyweight bout between health care colossus Johnson & Johnson (JNJ 0.22%) and diversified pharmaceutical giant Novartis (NVS -0.13%). Watch and find out which stock gets eliminated and which will advance to the next round.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.